Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04057365 · ClinicalTrials.gov registry record · Phase 2
Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC)
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Terminated
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT04057365: Clinical Trial Phase 2 study, sponsored by Massachusetts General Hospital.
NCT04057365 is a Phase 2 study that was terminated before completion, run by Massachusetts General Hospital. The registered enrollment target is 15 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04057365, a Phase 2 study, was terminated before completion, sponsored by Massachusetts General Hospital.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
This research is studying the effect of the combination of how two study drugs (Nivolumab and DKN-01) works in people with advanced biliary tract cancer.
Interventions
- DRUG Nivolumab
- DRUG DKN-01
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2019-10-07 |
| Est. Completion | 2022-09-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04057365
The ClinicalTrials.gov registry entry for NCT04057365 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nivolumab is the first listed.
NCT04057365 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04057365 about?
NCT04057365 is a clinical study titled "Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC)". This research is studying the effect of the combination of how two study drugs (Nivolumab and DKN-01) works in people with advanced biliary tract cancer.
What is the current status of trial NCT04057365?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2019-10-07. Estimated completion is 2022-09-25.
What interventions are being tested in trial NCT04057365?
The interventions under investigation include: Nivolumab (DRUG), DKN-01 (DRUG).
Who is sponsoring clinical trial NCT04057365?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.